ViewRay secures FDA clearance for MRIdian upgrades
Image-guided radiation therapy developer ViewRay has received clearance from...Read more on AuntMinnie.comRelated Reading: New orders drive ViewRay revenue growth in 2018 ViewRay adds to revenue and net loss in Q3 ViewRay to launch pancreatic cancer trial ViewRay taps new CCO ViewRay announces $150M stock offering
Margin negative resection in pancreatic cancer remains the only curative option but is challenging, especially with the retroperitoneal margin. Intraoperative radiation therapy (IORT) can improve rates of local control but requires specially designed facilities and equipment. This retrospective review describes initial results of a novel implantable mesh of uni-directional low dose rate (LDR) Pd-103 sources (sheet) used to deliver a focal margin-directed high-dose boost in patients with concern for close or positive margins.
Justice Ruth Bader Ginsburg says she's cancer-free Thursday, January 9, 2020 Supreme Court Justice Ruth Bader Ginsburg says she's starting the new year cancer-free. The 86-year-old was "energized and speaking animatedly" when she told CNN, "I'm cancer free. That's good," during a rare sit-down interview from her chambers on Tuesday. This was the fourth time over the past 20 years Ginsburg has beaten cancer. She had colorectal cancer in 1999, pancreatic cancer in 2009 and lung cancer surgery... Was patient mislead? Told she was "cancer-free" after 3 weeks of radiation therapy
Publication date: Available online 16 September 2020Source: Practical Radiation OncologyAuthor(s): Michael D. Chuong, John Bryant, Kathryn E. Mittauer, Matthew Hall, Rupesh Kotecha, Diane Alvarez, Tino Romaguera, Muni Rubens, Sonia Adamson, Andrew Godley, Vivek Mishra, Gustavo Luciani, Alonso N. Gutierrez
and Purpose: The role of neoadjuvant radiation for resectable pancreatic adenocarcinoma is controversial. We performed a prospective dose-escalation study of neoadjuvant stereotactic body radiation therapy (SBRT) with concurrent capecitabine and elective nodal irradiation (ENI) followed by surgical resection to explore the toxicity and feasibility of this approach.
Few studies have examined the role of stereotactic body radiation (SBRT) after multiagent chemotherapy (ChT) in pancreatic ductal adenocarcinoma (PDAC). This was a prospective study of SBRT after ChT for PDAC.
The role of neoadjuvant radiation therapy for resectable pancreatic cancer is controversial. Locoregional failure is a large component of patient morbidity, with a significant proportion of patients dying with progression of local disease (Iacobuzio-Donahue CA, et al. JCO 2009). With recent advances in systemic disease control (Conroy T, et al. NEJM 2018), the role of local therapy may become increasingly important.
Different prognostic markers have been identified in pancreatic cancer, including blood-based and imaging-based biomarkers. For example, lymphopenia can occur in patients receiving radiation therapy (RT) and is associated with decreased survival in several malignancies, including pancreatic ductal adenocarcinoma (PDAC) (Venkatesulu B, et al. Crit Rev Oncol Hematol 2018). Notably, prior work showed that 5 fractions of pancreas stereotactic radiation therapy (SBRT) resulted in less lymphopenia and an improved overall survival (OS) than chemoradiation (CRT) given over 5-6 weeks (Wild A, et al.
The objective of the current study is to investigate the impact of the timing of immunotherapy with chemotherapy and radiation therapy (RT) on the overall survival (OS) of PDAC patients who did not receive surgical resection of the pancreatic tumor.Materials and Methods: Patients with pancreatic adenocarcinoma who did not receive surgical resection of the pancreatic tumor were identified from the National Cancer Database (NCDB). Cox proportional hazard models were employed to compare the OS between patients who received immunotherapy with chemotherapy or RT with a different sequence of treatment. The multivariable analysis...
Conclusions: In the early-stage AC, adjuvant therapy may not improve the outcome in the short term but may benefit over a long period. It should be considered, especially in patients with adverse risk factors. Radiation therapy may not be useful in managing AC in the adjuvant setting. PMID: 32849944 [PubMed]
Purpose of review Dose escalation radiation therapy such as those delivered by stereotactic body radiation therapy (SBRT) has shown to improve local disease control in multiple types of malignancies. This requires fiducial placement to improve accuracy of treatment and avoid adverse events to adjacent radiosensitive organs during respiration phases. The purpose of this review is to provide updates of recent high-quality articles related to endoscopic ultrasonography (EUS)-guided fiducial placement for gastrointestinal malignancies, particularly in pancreatic cancer, which is expected to be the second leading cause of can...